Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Abstract Objective: To evaluate the effect of cytotoxic chemotherapy on survival in patients with non-small cell lung cancer. Design: Meta-analysis using updated data on individual patients from all available randomised trials, both published and unpublished. Subjects: 9387 patients (7151 deaths) from 52 randomised clinical trials. Main outcome measure: Survival. Results: The results for modern regimens containing cisplatin favoured chemotherapy in all comparisons and reached conventional levels of significance when used with radical radiotherapy and with supportive care. Trials comparing surgery with surgery plus chemotherapy gave a hazard ratio of 0.87 (13% reduction in the risk of death, equivalent to an absolute benefit of 5% at five years). Trials comparing radical radiotherapy with radical radiotherapy plus chemotherapy gave a hazard ratio of 0.87 (13% reduction in the risk of death; absolute benefit of 4% at two years), and trials comparing supportive care with supportive care plus chemotherapy 0.73 (27% reduction in the risk of death; 10% improvement in survival at one year). The essential drugs needed to achieve these effects were not identified. No difference in the si Conclusion: At the outset of this meta-analysis there was considerable pessimism about the role of chemotherapy in non-small cell lung cancer. These results offer hope of progress and suggest that chemotherapy may have a role in treating this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Peto, R. (1987) · Statistics in Medicine · doi:10.1002/sim.4780060306 · Cited by 409
Cited by
Items 101–149 of 149
Smit, E. F., van Meerbeeck, J. P. A. M., Lianes, P., Debruyne, C., Legrand, C., Schramel, F., Smit, H., Gaafar, R., Biesma, B., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.195 · Cited by 351
Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment
Alduais, Y., Zhang, H., Fan, F., Chen, J., & Chen, B. (2023) · Medicine · doi:10.1097/md.0000000000032899 · Cited by 347
Arrieta, Ó., Angulo, L. P., Núñez-Valencia, C., Dorantes-Gallareta, Y., Macedo, E. O., Martínez-López, D., Alvarado, S., Corona-Cruz, J.-F., & Oñate-Ocaña, L. F. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2793-5 · Cited by 346
Georgoulias, V, Papadakis, E., Alexopoulos, A., Tsiafaki, X., Rapti, A., Veslemes, M., Palamidas, P., & Vlachonikolis, I. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04644-4 · Cited by 346
Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis
Lacas, B., Bourhis, J., Overgaard, J., Zhang, Q., Grégoire, V., Nankivell, M., Zackrisson, B., Szutkowski, Z., Suwiński, R., Poulsen, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30458-8 · Cited by 345
Emerging therapeutic agents for advanced non-small cell lung cancer
Chen, R., Manochakian, R., James, L., Azzouqa, A.-G., Shi, H., Zhang, Y., Zhao, Y., Zhou, K., & Lou, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00881-7 · Cited by 340
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Ramalingam, S., & Belani, C. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s1-5 · Cited by 333
Asmis, T. R., Ding, K., Seymour, L., Shepherd, F. A., Leighl, N. B., Winton, T. L., Whitehead, M., Spaans, J. N., Graham, B. C., & Goss, G. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.8322 · Cited by 332
Ceppi, P., Volante, M., Novello, S., Rapa, I., Danenberg, K. D., Danenberg, P. V., Cambieri, A., Selvaggi, G., Saviozzi, S., Calogero, R., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl300 · Cited by 323
Gilligan, D., Nicolson, M., Smith, I., Groen, H., Dalesio, O., Goldstraw, P., Hatton, M., Hopwood, P., Manegold, C., Schramel, F., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60714-4 · Cited by 323
Refining the treatment of NSCLC according to histological and molecular subtypes
Thomas, A., Liu, S. V., Subramaniam, D. S., & Giaccone, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.90 · Cited by 321
Brodowicz, T., Krzakowski, M., Zwitter, M., Tzekova, V., Ramlau, R., Ghilezan, N., Ciuleanu, T., Cucevic, B., Gyurkovits, K., Ulsperger, E., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.01.006 · Cited by 320
Smith, I. E., O’Brien, M. E. R., Talbot, D. C., Nicolson, M. C., Mansi, J. L., Hickish, T. F., Norton, A., & Ashley, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1336 · Cited by 308
Roszkowski, K., Pluzanska, A., Krzakowski, M., Smith, A. P., Saigi, E., Aasebo, U., Parisi, A., Pham Tran, N., Olivares, R., & Berille, J. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)00094-5 · Cited by 308
Paclitaxel Resistance in Non–Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations
Monzó, M., Rosell, R., Sánchez, J. J., Lee, J. S., O'Brate, A., González-Larriba, J. L., Alberola, V., Lorenzo, J. C., Núñez, L., Ro, J. Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1786 · Cited by 306
Rosell, R., Gatzemeier, U., Betticher, D. C., Keppler, U., Macha, H. N., Pirker, R., Berthet, P., Breau, J. L., Lianes, P., Nicholson, M., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf332 · Cited by 299
A Translational View of the Molecular Pathogenesis of Lung Cancer
Sato, M., Shames, D. S., Gazdar, A. F., & Minna, J. D. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000263718.69320.4c · Cited by 297
Mac Manus, M. P., Hicks, R. J., Matthews, J. P., Hogg, A., McKenzie, A. F., Wirth, A., Ware, R. E., & Ball, D. L. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01477-8 · Cited by 297
Local recurrence after surgery for early stage lung cancer: An 11‐year experience with 975 patients
Kelsey, C. R., Marks, L. B., Hollis, D., Hubbs, J. L., Ready, N. E., D'Amico, T. A., & Boyd, J. A. (2009) · Cancer · doi:10.1002/cncr.24625 · Cited by 295
Aupérin, A., Le Péchoux, C., Pignon, J. P., Koning, C., Jeremic, B., Clamon, G., Einhorn, L., Ball, D., Trovo, M. G., Groen, H. J. M., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj117 · Cited by 293
Gurubhagavatula, S., Liu, G., Park, S., Zhou, W., Su, L., Wain, J. C., Lynch, T. J., Neuberg, D. S., & Christiani, D. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.067 · Cited by 292
Wu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D. S. W., Yang, J. C.-H., Azrif, M., Mitsudomi, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 291
Rusch, V. W., Giroux, D. J., Kraut, M. J., Crowley, J., Hazuka, M., Johnson, D., Goldberg, M., Detterbeck, F., Shepherd, F., Burkes, R., et al. (2001) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2001.112465 · Cited by 287
ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer
Simon, G. R., Sharma, S., Cantor, A., Smith, P., & Bepler, G. (2005) · Chest · doi:10.1378/chest.127.3.978 · Cited by 277
on behalf of the Hokkaido Lung Cancer Clinical Study Group, Asahina, H., Yamazaki, K., Kinoshita, I., Sukoh, N., Harada, M., Yokouchi, H., Ishida, T., Ogura, S., Kojima, T., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603393 · Cited by 277
Le Chevalier, T., Scagliotti, G., Natale, R., Danson, S., Rosell, R., Stahel, R., Thomas, P., Rudd, R. M., Vansteenkiste, J., Thatcher, N., et al. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.10.014 · Cited by 277
Ramalingam, S. S., Maitland, M. L., Frankel, P., Argiris, A. E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E. E., Gandara, D. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9094 · Cited by 273
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer
Nagasaka, M., & Gadgeel, S. M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1409624 · Cited by 270
Robinet, G., Thomas, P., Breton, J. L., Léna, H., Gouva, S., Dabouis, G., Bennouna, J., Souquet, P. J., Balmes, P., Thiberville, L., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008338312647 · Cited by 264
Fry, W. A., Phillips, J. L., & Menck, H. R. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991101)86:9<1867::aid-cncr31>3.0.co;2-9 · Cited by 263
Kosmidis, P., Mylonakis, N., Nicolaides, C., Kalophonos, C., Samantas, E., Boukovinas, J., Fountzilas, G., Skarlos, D., Economopoulos, T., Tsavdaridis, D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.112 · Cited by 255
Douillard, J.-Y., Tribodet, H., Aubert, D., Shepherd, F. A., Rosell, R., Ding, K., Veillard, A.-S., Seymour, L., Le Chevalier, T., Spiro, S., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c814e7 · Cited by 252
Lipoplatin Formulation Review Article
Stathopoulos, G. P., & Boulikas, T. (2012) · Journal of Drug Delivery · doi:10.1155/2012/581363 · Cited by 224
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly
Schild, S. E., Stella, P. J., Geyer, S. M., Bonner, J. A., McGinnis, W. L., Mailliard, J. A., Brindle, J., Jatoi, A., & Jett, J. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.019 · Cited by 222
Long-term results of combined-modality therapy in resectable non-small-cell lung cancer.
Martin, J., Ginsberg, R. J., Venkatraman, E. S., Bains, M. S., Downey, R. J., Korst, R. J., Kris, M. G., & Rusch, V. W. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.092 · Cited by 195
Di Maio, M., Chiodini, P., Georgoulias, V., Hatzidaki, D., Takeda, K., Wachters, F. M., Gebbia, V., Smit, E. F., Morabito, A., Gallo, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5844 · Cited by 181
Michiels, S., Piedbois, P., Burdett, S., Syz, N., Stewart, L., & Pignon, J.-P. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462305050154 · Cited by 154
The clinical significance of quality of life assessments in oncology: a summary for clinicians
Sloan, J. A., Frost, M. H., Berzon, R., Dueck, A., Guyatt, G., Moinpour, C., Sprangers, M., Ferrans, C., Cella, D., & Clinical Significance Consensus Meeting Group (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0085-y · Cited by 149
O’Brien, M. E. R., Anderson, H., Kaukel, E., O’Byrne, K., Pawlicki, M., von Pawel, J., & Reck, M. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh220 · Cited by 139
Advances in global change research require open science by individual researchers
Wolkovich, E. M., Regetz, J., & O'Connor, M. I. (2012) · Global Change Biology · doi:10.1111/j.1365-2486.2012.02693.x · Cited by 111
Karampeazis, A., Voutsina, A., Souglakos, J., Kentepozidis, N., Giassas, S., Christofillakis, C., Kotsakis, A., Papakotoulas, P., Rapti, A., Agelidou, M., et al. (2013) · Cancer · doi:10.1002/cncr.28132 · Cited by 113
Lima, A. B. C., Macedo, L. T., & Sasse, A. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022681 · Cited by 92
Kubota, K., Kawahara, M., Ogawara, M., Nishiwaki, Y., Komuta, K., Minato, K., Fujita, Y., Teramukai, S., Fukushima, M., & Furuse, K. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70261-4 · Cited by 75
Treat, J. A., Gonin, R., Socinski, M. A., Edelman, M. J., Catalano, R. B., Marinucci, D. M., Ansari, R., Gillenwater, H. H., Rowland, K. M., Comis, R. L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp352 · Cited by 70
Morabito, A., Gebbia, V., Di Maio, M., Cinieri, S., Viganò, M. G., Bianco, R., Barbera, S., Cavanna, L., De Marinis, F., Montesarchio, V., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.04.008 · Cited by 53
Developing biomarker-specific end points in lung cancer clinical trials
Neal, J. W., Gainor, J. F., & Shaw, A. T. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.222 · Cited by 51
Georgoulias, V., Androulakis, N., Kotsakis, A., Hatzidaki, D., Syrigos, K., Polyzos, A., Agelidou, A., Varthalitis, I., Ziras, N., Agelidou, M., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.07.021 · Cited by 44
Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer
Yap, T. A., Macklin-Doherty, A., & Popat, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.014 · Cited by 38
de Jong, C., Herder, G. J. M., & Deneer, V. H. M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13683 · Cited by 8
Metadata
- Authors
- Non-small Cell Lung Cancer Collaborative Group
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1995-10-07
- Volume
- 311
- Issue
- 7010
- Pages
- 899-909
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W4239714259
- Cited by
- 2,850
- References
- 3
- FWCI
- 48.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.